Mobile Health Intervention for Pediatric PAH
(MhOVE-PPH Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you must have a stable PAH-specific medication regimen for three months before joining the trial, with only minor adjustments allowed.
What data supports the effectiveness of the mHealth Intervention treatment for Pediatric PAH?
Research shows that mobile health (mHealth) interventions have been effective in managing chronic diseases in children, such as obesity and asthma, by improving health behaviors and monitoring. This suggests that similar mHealth approaches could be beneficial for managing Pediatric PAH (Pulmonary Arterial Hypertension).12345
Is the mobile health intervention generally safe for use in humans?
The research on mobile health (mHealth) interventions, while focused on different conditions like obesity and physical inactivity, suggests they are generally safe for use in humans. However, challenges such as data security, patient privacy, and potential increased screen time need to be considered.678910
How is the mHealth Intervention treatment for Pediatric PAH different from other treatments?
The mHealth Intervention for Pediatric PAH is unique because it uses mobile technology to deliver health programs, making it more accessible and potentially more engaging for children and adolescents. Unlike traditional treatments, it focuses on self-management and behavior change through interactive apps, which can be tailored to individual needs and preferences.611121314
What is the purpose of this trial?
Children and adults with pulmonary arterial hypertension (PAH) have severely reduced daily activity compared to healthy populations. In adults, investigators recently demonstrated that lower baseline daily step counts associated with increased risk of hospitalization and worsening WHO functional class; similarly, reduced step counts associate with hospitalization in children with PAH. This application builds on our recently completed NIH-funded pilot mobile health (mHealth) trial in adult patients with PAH which demonstrated the ability to remotely increase step counts. The investigators now aim to: (1) adapt our mHealth intervention to the developmental needs and interests of adolescents; and, (2) determine if our intervention increases step counts in adolescents, providing the foundation for a larger trial to assess the impact on quality of life and clinical outcomes.
Research Team
Eric Austin, MD
Principal Investigator
Vanderbilt University Medical Center
Eligibility Criteria
This trial is for adolescents aged 13-19 with pulmonary arterial hypertension (PAH). They must have been on a stable PAH medication regimen for at least three months and have a WHO functional class of I-III. It's open to those with idiopathic, heritable, or associated PAH, as well as PAH from simple congenital heart disease.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a mobile health intervention to increase step counts, monitored using a Fitbit device
Follow-up
Participants are monitored for changes in quality of life and clinical outcomes after the intervention
Treatment Details
Interventions
- mHealth Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vanderbilt University Medical Center
Lead Sponsor
University of California, San Francisco
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator